Hourly brief: Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?. NG=F is -0.15% as traders track the next scheduled catalyst. What happened: Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?; You Won't Regret Buying These 3 Dividend Stocks in July; 1 Canadian Dividend Stock Down 44% to Buy and Hold Forever; AI data center builder Crusoe reportedly raising $3B at $30B valuation; Tesla Beat Delivery Estimates by 74,000 Vehicles -- and the Stock Had Its Worst Day in Nearly a Year. Here's Why.. Market moves: NG=F -0.15%, TNX +0.11%, HG=F +0.06%, ETH +0.03%, BTC -0.02%, SI=F -0.01%. Coming up: no high-impact scheduled catalyst is visible in the current window. Continuing story: Hourly brief: Micron vs. Intel: Which AI Stock Is the Better Buy?.